title: A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine.
abstract: OBJECTIVE
  This article explores the application of cost-effectiveness analysis in a comparison of eletriptan and sumatriptan in the acute treatment of migraine.
  
  
  METHODS
  The study employs data from a randomized, double-blind, placebo-controlled clinical trial comparison of oral eletriptan (40 and 80 mg) and oral sumatriptan (50 and 100 mg). Analyses were undertaken using two composite measures of treatment outcome constructed to reflect the requirements of patients more comprehensively than the conventional efficacy indicator of headache response at 2 hours. On the cost side of the equation, reflecting the health-care system perspective of the analysis, drug costs for initial dosing, second dosing for nonresponse, and recurrence and rescue medication were taken into account.
  
  
  RESULTS
  The analysis found that eletriptan treatment resulted in lower costs per successfully treated attack than those of sumatriptan under both outcome criteria.
  
  
  CONCLUSIONS
  Further refinement of outcomes measurement in migraine would be valuable and eletriptan has a potentially important role to play in the cost-effective management of the disorder.
authors.affiliation: Outcomes Research, Pfizer Global Research and Development, Sandwich, UK. Nicholas_Wells@sandwich.pfizer.com
authors.forename: Nicholas
authors.initials: N
authors.lastname: Wells
authors.forename: Jayasena
authors.initials: J
authors.lastname: Hettiarachchi
authors.forename: Michael
authors.initials: M
authors.lastname: Drummond
authors.forename: Mcom
authors.initials: M
authors.lastname: DPhil
authors.forename: David
authors.initials: D
authors.lastname: Carter
authors.forename: Tamiza
authors.initials: T
authors.lastname: Parpia
authors.forename: Francis
authors.initials: F
authors.lastname: Pang
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000191:economics*; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000191:economics; D010919:Placebos; D011759:Pyrrolidines / Q000008:administration & dosage* / Q000191:economics*; D018170:Sumatriptan / Q000008:administration & dosage* / Q000191:economics*; D016896:Treatment Outcome; D014363:Tryptamines; D006113:United Kingdom; D014662:Vasoconstrictor Agents / Q000008:administration & dosage* / Q000191:economics*
chemical_list: D007211:Indoles; D010919:Placebos; D011759:Pyrrolidines; D014363:Tryptamines; D014662:Vasoconstrictor Agents; C115647:eletriptan; D018170:Sumatriptan